GJB2 and neoplasm: Besides, the in vivo data showed that administration of gefitinib (100 mg/kg per day, gavaged orally) led to more significant inhibition of HCC827-mock tumor xenografts than HCC827-Cx26 xenografts, compared with vehicle groups (Figure 4h).